
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Institute of Clinical Pathology [M. S., S. F. S., C. L., R. H., P. B.], Institute of Neurology [T. S.], and the Department of Medical Computer Sciences, Section of Clinical Biometrics [H. H.], University of Vienna, A-1090 Vienna, Austria
Purpose: Id (inhibitor of differentiation/DNA binding) -1 is involved in neoangiogenesis, it antagonizes basic helix-loop-helix proteins, inhibits differentiation, and enhances cell proliferation. Aim of this study was to investigate Id-1 protein expression in epithelial ovarian tumors and its clinical relevance in ovarian cancer.
Experimental Design: We have investigated Id-1 expression by reverse transcription-PCR and Western blotting in ovarian cancer samples. On the basis of these results, Id-1 protein expression was determined by immunohistochemistry in 101 specimens of epithelial ovarian cancer, in 40 borderline tumors, and in 20 cystadenomas. In these cases, Id-1 expression was correlated with p21 expression, microvessel density, and survival.
Results: By immunohistochemistry, detectable expression of Id-1 was found significantly more often in ovarian cancers (74.3%) than in borderline tumors (32.5%) and cystadenomas (0%; P < 0.0001,
2 test). Cancer samples with poor or moderate histological differentiation (G3/G2) showed significantly stronger Id-1 expression than cancer samples with high differentiation (G1; P = 0.021, Mann-Whitney test), and no association of Id-1 with p21 expression or microvessel density was found. In cancer samples strong or moderate expression of Id-1 was a strong predictor for shorter overall survival in uni- and multivariate analysis (P = 0.001, Cox-regression).
Conclusions: The level of Id-1 protein expression correlates with the malignant potential of ovarian tumors. In cancer samples, stronger Id-1 expression is associated with poor differentiation and more aggressive behavior of tumor cells, resulting in poor clinical outcome. Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.
This article has been cited by other articles:
![]() |
R. Salomon, L. Young, D. MacLeod, X.-L. Yu, and Q. Dong Probasin Promoter-driven Expression of ID1 Is not Sufficient for Carcinogenesis in Rodent Prostate J. Histochem. Cytochem., June 1, 2009; 57(6): 599 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Qian and X. Chen ID1, Inhibitor of Differentiation/DNA Binding, Is an Effector of the p53-dependent DNA Damage Response Pathway J. Biol. Chem., August 15, 2008; 283(33): 22410 - 22416. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kamalian, J. R. Gosney, S. S. Forootan, C. S. Foster, Z. Z. Bao, C. Beesley, and Y. Ke Increased Expression of Id Family Proteins in Small Cell Lung Cancer and its Prognostic Significance Clin. Cancer Res., April 15, 2008; 14(8): 2318 - 2325. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Gautschi, C. G. Tepper, P. R. Purnell, Y. Izumiya, C. P. Evans, T. P. Green, P. Y. Desprez, P. N. Lara, D. R. Gandara, P. C. Mack, et al. Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer Cancer Res., April 1, 2008; 68(7): 2250 - 2258. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Tsunedomi, N. Iizuka, T. Tamesa, K. Sakamoto, T. Hamaguchi, H. Somura, M. Yamada, and M. Oka Decreased ID2 Promotes Metastatic Potentials of Hepatocellular Carcinoma by Altering Secretion of Vascular Endothelial Growth Factor Clin. Cancer Res., February 15, 2008; 14(4): 1025 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, M.-T. Ling, Q. Wang, C.-K. Lau, S. C. L. Leung, T. K. Lee, A. L. M. Cheung, Y.-C. Wong, and X. Wang Identification of a Novel Inhibitor of Differentiation-1 (ID-1) Binding Partner, Caveolin-1, and Its Role in Epithelial-Mesenchymal Transition and Resistance to Apoptosis in Prostate Cancer Cells J. Biol. Chem., November 16, 2007; 282(46): 33284 - 33294. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Moll, C. Millet, D. Noel, B. Orsetti, A. Bardin, D. Katsaros, C. Jorgensen, M. Garcia, C. Theillet, P. Pujol, et al. Chordin is underexpressed in ovarian tumors and reduces tumor cell motility FASEB J, February 1, 2006; 20(2): 240 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Ling, T. C.M. Lau, C. Zhou, C. W. Chua, W. K. Kwok, Q. Wang, X. Wang, and Y.-C. Wong Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF) Carcinogenesis, October 1, 2005; 26(10): 1668 - 1676. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kebebew, M. Peng, P. A. Treseler, O. H. Clark, Q.-Y. Duh, D. Ginzinger, and R. Miner Id1 Gene Expression Is Up-Regulated in Hyperplastic and Neoplastic Thyroid Tissue and Regulates Growth and Differentiation in Thyroid Cancer Cells J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6105 - 6111. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. Cheung, M.-t. Ling, S. W. Tsao, Y.C. Wong, and X. Wang Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells Carcinogenesis, June 1, 2004; 25(6): 881 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Coppe, Y. Itahana, D. H. Moore, J. L. Bennington, and P.-Y. Desprez Id-1 and Id-2 Proteins as Molecular Markers for Human Prostate Cancer Progression Clin. Cancer Res., March 15, 2004; 10(6): 2044 - 2051. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fong, Y. Itahana, T. Sumida, J. Singh, J.-P. Coppe, Y. Liu, P. C. Richards, J. L. Bennington, N. M. Lee, R. J. Debs, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis PNAS, November 11, 2003; 100(23): 13543 - 13548. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K.-W. Lee, K. Man, M.-T. Ling, X.-H. Wang, Y.-C. Wong, C.-M. Lo, R. T.-P. Poon, I. O.-L. Ng, and S.-T. Fan Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway Carcinogenesis, November 1, 2003; 24(11): 1729 - 1736. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G. Shepherd and M. W. Nachtigal Identification of a Putative Autocrine Bone Morphogenetic Protein-Signaling Pathway in Human Ovarian Surface Epithelium and Ovarian Cancer Cells Endocrinology, August 1, 2003; 144(8): 3306 - 3314. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |